Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Current Deferred Revenue: 2022-2024

Historic Current Deferred Revenue for Dianthus Therapeutics (DNTH) over the last 2 years, with Dec 2024 value amounting to $479,000.

  • Dianthus Therapeutics' Current Deferred Revenue rose 854.00% to $954,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $954,000, marking a year-over-year increase of 854.00%. This contributed to the annual value of $479,000 for FY2024, which is N/A change from last year.
  • Latest data reveals that Dianthus Therapeutics reported Current Deferred Revenue of $479,000 as of FY2024, which was up 379.00% from $100,000 recorded in FY2022.
  • In the past 5 years, Dianthus Therapeutics' Current Deferred Revenue ranged from a high of $479,000 in FY2024 and a low of $100,000 during FY2022.
  • In the last 2 years, Dianthus Therapeutics' Current Deferred Revenue had a median value of $289,500 in 2022 and averaged $289,500.